David T. Riglar

David T. Riglar

Auto-generated profile, based on publicly available information

David T. Riglar

Department of infectious disease, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
DRDavid T. Riglar
David T. Riglar
PSPamela A. Silver
Pamela A. Silver
Our ability to generate bacterial strains with unique and increasingly complex functions has rapidly expanded in recent times. The capacity for DNA synthesis is increasing and costing less; new tools are being developed for fast, large-scale genetic manipulation; and more tested genetic parts are available for use, as is the knowledge of how to use them effectively. These advances promise to unlock an exciting array of 'smart' bacteria for clinical use but will also challenge scientists to better optimize preclinical testing regimes for early identification and validation of promising strains and strategies. Here, we review recent advances in the development and testing of engineered bacterial diagnostics and therapeutics. We highlight new technologies that will assist the development of more complex, robust and reliable engineered bacteria for future clinical applications, and we discuss approaches to more efficiently evaluate engineered strains throughout their preclinical development.

29 May 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
DRDavid T Riglar
David T Riglar
TGTobias Giessen
Tobias Giessen
MBMichael Baym
Michael Baym
SKS Jordan Kerns
S Jordan Kerns
MNMatthew J Niederhuber
Matthew J Niederhuber
PSPamela A Silver
Pamela A Silver

1 January 2011 in Cell Host & Microbe
Verified
Journal Article
Closed access
DRDavid T. Riglar
David T. Riglar
DRDave Richard
Dave Richard
DWDanny W. Wilson
Danny W. Wilson
MBMichelle J. Boyle
Michelle J. Boyle
CDChaitali Dekiwadia
Chaitali Dekiwadia
JBJake Baum
Jake Baum

26 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MBMichelle J. Boyle
Michelle J. Boyle
DWDanny W. Wilson
Danny W. Wilson
JRJack Richards
Jack Richards
DRDavid T. Riglar
David T. Riglar
KTKevin K. A. Tetteh
Kevin K. A. Tetteh
JBJames G. Beeson
James G. Beeson
During blood-stage infection by Plasmodium falciparum, merozoites invade RBCs. Currently there is limited knowledge of cellular and molecular invasion events, and no established assays are available to readily measure and quantify invasion-inhibitory antibodies or compounds for vaccine and drug studies. We report the isolation of viable merozoites that retain their invasive capacity, at high purity and yield, purified by filtration of highly synchronous populations of schizonts. We show that the half-life of merozoite invasive capacity after rupture is 5 min at 37 °C, and 15 min at room temperature. Studying the kinetics of invasion revealed that 80% of invasion events occur within 10 min of mixing merozoites and RBCs. Invasion efficiency was maximum at low merozoite-to-RBC ratios and occurred efficiently in the absence of serum and with high concentrations of dialyzed nonimmune serum. We developed and optimized an invasion assay by using purified merozoites that enabled invasion-inhibitory activity of antibodies and compounds to be measured separately from other mechanisms of growth inhibition; the assay was more sensitive for detecting inhibitory activity than established growth-inhibition assays. Furthermore, with the use of purified merozoites it was possible to capture and fix merozoites at different stages of invasion for visualization by immunofluorescence microscopy and EM. We thereby demonstrate that processing of the major merozoite antigen merozoite surface protein-1 occurs at the time of RBC invasion. These findings have important implications for defining invasion events and molecular interactions, understanding immune interactions, and identifying and evaluating inhibitors to advance vaccine and drug development.

1 May 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DRDave Richard
Dave Richard
CMChris Macraild
Chris Macraild
DRDavid T. Riglar
David T. Riglar
JCJo-Anne Chan
Jo-Anne Chan
MFMichael Foley
Michael Foley
ACAlan F. Cowman
Alan F. Cowman
Invasion of host cells by apicomplexan parasites, including Plasmodium falciparum and Toxoplasma gondii, is a multistep process. Central to invasion is the formation of a tight junction, an aperture in the host cell through which the parasite pulls itself before settling into a newly formed parasitophorous vacuole. Two protein groups, derived from different secretory organelles, the micronemal protein AMA1 and the rhoptry proteins RON2, RON4, and RON5, have been shown to form part of this structure, with antibodies targeting P. falciparum AMA1 known to inhibit invasion, probably via disruption of its association with the PfRON proteins. Inhibitory AMA1-binding peptides have also been described that block P. falciparum merozoite invasion of the erythrocyte. One of these, R1, blocks invasion some time after initial attachment to the erythrocyte and reorientation of the merozoite to its apical pole. Here we show that the R1 peptide binds the PfAMA1 hydrophobic trough and demonstrate that binding to this region prevents its interaction with the PfRON complex. We show that this defined association between PfAMA1 and the PfRON complex occurs after reorientation and engagement of the actomyosin motor and argue that it precedes rhoptry release. We propose that the formation of the AMA1-RON complex is essential for secretion of the rhoptry contents, which then allows the establishment of parasite infection within the parasitophorous vacuole.

25 November 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JFJamie I. Fletcher
Jamie I. Fletcher
SMSarina Meusburger
Sarina Meusburger
CHChristine Hawkins
Christine Hawkins
DRDavid T. Riglar
David T. Riglar
Erinna LeeErinna Lee
Erinna Lee
JAJerry M. Adams
Jerry M. Adams
A central issue in the control of apoptosis is whether its essential mediators Bax and Bak must be restrained by Bcl-2-like prosurvival relatives to prevent their damaging mitochondria and unleashing apoptosis. The issue is particularly vexed for Bax, which is largely a cytosolic monomer in unstressed cells. To determine whether Bax regulation requires its binding by prosurvival relatives, we replaced a conserved aspartate in its BH3 interaction domain with arginine. Bax D68R functioned and behaved like wild-type Bax in localization and activation but had greatly impaired binding to the prosurvival family members. Nevertheless, Bcl-x L remained able to block apoptosis induced by Bax D68R. Whereas cells with sufficient Bcl-x L tolerated expression of Bax D68R, it provoked apoptosis when Bcl-x L was absent, downregulated, or inactivated. Moreover, Bax D68R rendered membrane bound by a C-terminal anchor mutation overwhelmed endogenous Bcl-x L and killed cells. These unexpected results suggest that engagement of Bax by its prosurvival relatives is a major barrier to its full activation. We propose that the Bcl-2-like proteins must capture the small proportion of Bax molecules with an exposed BH3 domain, probably on the mitochondrial membrane, to prevent Bax-imposed cell death, but that Bcl-x L also controls Bax by other mechanisms.